Abstract
Cell fusion techniques were used to derive mammalian host cell lines suitable for large-scale production of therapeutic proteins. Although the 293S cell line, of human embryonic kidney origin, is an excellent host cell for mammalian gene expression, these cells have a tendency to form large and tight aggregates in suspension cultures and bioreactors. To solve the problem of aggregation, 293S cells were fused to a human suspension cell line, 2B8 (a Burkitt's lymphoma derivative), using polyethylene glycol (PEG). The PEG-treated 293S and 2B8 cells were selected in a medium supplemented with hypoxanthine-aminopterin-thymidine and G418 (1 mg/ml) to eliminate nonfused cells. These hybrid clones, designated as HKB (hybrid of kidney and B cells), are negative for endogenous immunoglobulin expression. Most clones are readily adaptable to serum-free suspension culture under shaking conditions without forming large and tight aggregates. One clone, HKB11, was shown to support high-level expression of cytokines [interleukin (IL)-2 and IL-4], ICAM-1 and rFVIII in a side-by-side comparison with 293 and Chinese hamster ovary cells. The above-described characteristics of HKB cells indicate that HKB11 is a favorable cell host for the production of human therapeutic proteins.
Similar content being viewed by others
References
Alt FW, Kellems RE, Bertino JR, Shimke RT. Selective multiplication of dihydrofolate reductase genes in methotrexate-resistant variants of cultured murine cells. J Biol Chem 253:1357–1370;1978.
Cho MS, Gissman L, Hayward SD. Epstein-Barr virus (P3HR-1) defective DNA codes for components of both the early antigen and viral capsid antigen complexes. Virology 137:9–19;1984.
Cho MS, Tran VM. Enhance protein production method. US Patent Number 5,854,021,1998.
Cho MS, Yee H, Brown C, Jeang KT, Chan S. An oriP expression vector containing the HIV-1 Tat/TAR transactivation axis produces high levels of protein expression in mammalian cells. Cytotechnology, in press.
Countryman J, Jenson H, Seibl R, Wolf H, Miller G. Polymorphic proteins encoded within BZLF1 of defective and standard Epstein-Barr viruses disrupt latency. J Virol 61:3672–3679;1987.
Eaton DL, Wood WI, Eaton D, Haas PE, Hollingshead P, Wion K, Mather J, Lawn RM, Vehar GA, Gorman C. Construction and characterization of an active factor VIII variant lacking the central one-third of the molecule. Biochemistry 25:8343–8347;1986.
Ferrari J, Gunson J, Lofgren J, Krummen L, Warner TG. Chinese hamster ovary cells with constitutively expressed sialidase antisense RNA produce recombinant DNAse in batch culture with increased sialic acid. Biotechnol Bioeng 60:589–593;1998.
Fresen KO, zur Hausen H. Establishment of EBNA-expressing cell lines by infection of Epstein-Barr virus (EBV)-genome-negative human lymphoma cells with different EBV strains. Int J Cancer 17:161–166;1976.
Graham FL, Smiley J, Russel WC, Narin R. Characteristics of a human cell line transformed by DNA from human adenovirus 5. J Gen Virol 36:137–148;1977.
Henle G, Henle W. Immunofluorescence in cells derived from Burkitt's lymphoma. J Bacteriol 91:1248–1256;1966.
Jassal R, Jenkins N, Charlwood J, Camilleri P, Jefferis R, Lund J. Sialylation of human IgG-Fc carbohydrate by transfected rat α(2,6) sialyl-transferase. Biochem Biophys Res Commun 286:243–249;2001.
Jenkins N, Parekh RB, James DC. Getting the glycosylation right: Implications for the biotechnology industry. Nat Biotechnol 14:975–981;1996.
Kennett RH. Cell fusion. Methods Enzymol 58:345–359;1979.
McClelland A, deBear J, Yost SC, Meyer AM, Marlor CW, Greve JM. Identification of monoclonal antibody epitopes and critical residues for rhinovirus binding in domain 1 of intercellular adhesion molecule 1. Proc Natl Acad Sci USA 88:7993–7997;1991.
Rabson M, Heston L, Miller G. Identification of a rare Epstein-Barr virus variant that enhances early antigen expression in Raji cells. Proc Natl Acad Sci USA 87:3660–3664;1983.
Reedman BM, Klein G. Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and nonproducer lymphoblastoid cell lines. Int J Cancer 11:499–520;1973.
Siadak AW, Lostrom ME. Cell-driven viral transformation. In: Engleman EG, Fong SKH, Larrick J, Raubitschek A, eds. Human Hybridomas and Monoclonal Antibodies. New York, Plenum Press, 167–185;1984.
Stillman BW, Gluzman Y. Replication and supercoiling of simian virus 40 DNA in cell extracts from human cells. Mol Cell Biol 5:2051–2060;1985.
Szybalska E, Szybalski W. Genetics of human cell line. IV. DNA-mediated hereditable transformation of a biochemical trait. Proc Natl Acad Sci USA 48:2026–2034;1962.
Szybalski W, Szybalska EH, Ragni G. Genetic studies with human cell lines. Natl Cancer Inst Monogr 7:75;1962.
Umana P, Jean-Mairet J, Baily JE. Tetracycline-regulated overexpression of glycosyltransferases in Chinese hamster ovary cells. Biotechnol Bioeng 65:542–549;1999.
Umana P, Jean-Mairet J, Moudry R, Amstutz H, Bailey JE. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol 17:176–180;1999.
Urlaub G, Chasin LA. Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity. Proc Natl Acad Sci USA 77:4216–4220;1980.
Warner TG. Enhancing therapeutic glycoprotein production in Chinese hamster ovary cells by metabolic engineering endogenous gene control with antisense DNA and gene targeting. Glycobiology 9:841–850;1999.
Weikert S, Papac D, Briggs J, Cowfer D, Tom S, Gawlitzek M, Lofgren J, Mehta S, Chisholm V, Modi N, Eppler S, Carroll K, Chamow S, Peers D, Berman P, Krummen L. Engineering Chinese ovary hamster cells to maximize sialic acid content of recombinant glycoproteins. Nat Biotechnol 17:1116–1121;1999.
Weintraub H, Genetta T, Kadesch T. Tissue-specific gene activation by MyoD: Determination of specificity bycis-acting repression elements. Genes Dev 8:2203–2211;1994.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cho, M.S., Yee, H. & Chan, S. Establishment of a human somatic hybrid cell line for recombinant protein production. J Biomed Sci 9, 631–638 (2002). https://doi.org/10.1007/BF02254991
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02254991